Podocytes dysfunction is a common feature as developing kidney diseases. In particular, the breakdown of the slit diaphragm in podocytes could be a key process in the developing of glomerulosclerosis. However, the mechanism remains unclear. A recent study demonstrated that a serine protease inhibitor protects podocyte from chronic kidney disease in rats, suggesting the activation of serine proteases could be a potential mechanism for podocyte injury. In this study, we examined the role of serine proteases in glomerular injury of Adriamycin (ADR) nephropathy in mice. METHODS: ADR at a dose of 10.5 mg/kg body weight was injected via the tail vein of BALB/c mice to develop ADR nephropathy. Glomeruli were isolated from mice using a magnetic particle concentrator after Dynabeads were systemically perfused. Serine protease activity in glomeruli was examined by Boc-QAR-AMC Fluorogenic Peptide Substrate. Nafamostat, a serine protease inhibitor, at a dose of 30 mg/kg body weight was intraperitoneally injected to mice with ADR nephropathy three times a week for 4 weeks. RESULTS: ADR administration induced glomerular injuries with an increase in urinary albumin excretion in mice. The glomerular mRNA expressions of Podocin, Synaptopodin and WT-1 were significantly reduced in ADR mice compared with control mice. The location of Podocin was disturbed and the number of WT1-positive cells was also decreased in the glomeruli of ADR mice. Glomerular serine protease activity was enhanced by ADR administration in mice.We first examined the potency of Nafamostat, which is known to be non-specific serine protease inhibitor. A protease activity assay demonstrated that Nafamostat inhibited thrombin activity, a serine protease, in dose dependent manner, with the half maximal inhibitory concentration (IC50) being 99nM, suggesting that Nafamostat was potent enough to block serine protease activity. Based on these results, we treated ADR mice with Nafamostat from day15 to day42. We found that the development of glomerulosclerosis and podocyte damages were significantly suppressed by Nafamostat. Urinary albumin creatinine ratio (uACR) (mg/g) of vehicle control group was 3328.5 6 528.6 at Day28 and 1955.5 6 233.8 at Day 42, whereas that of Nafamostat group was 1753.3 6 294.0 at Day28 and 1250.6 6 222.7 at Day42, showing that the treatment significantly reduced uACR. These results suggest that podocyte injury due to ADR was mediated by serine protease activation and was ameliorated by blocking serine protease inhibition. CONCLUSIONS: Serine protease activation might be a potential mechanism for podocyte injury in mouse ADR nephropathy. that has a phylogenetic homology with the junctional adhesion molecule (JAM) family and is highly expressed in renal proximal tubule. Here we investigated the pathogenic role of DICAM in cisplatin-induced acute tubular damage. METHODS: To induce acute tubular necrosis (ATN), cisplatin was given intraperitoneally to 8-to 10-week-old male DICAM knockout (KO) mice and their wild-type (WT) littermates. The severity of ATN was compared with a semi-quantitative histological score, immunostaining for lipocalin-2 (LCN2), caspase-3 and high mobility group box 1 (HMGB1), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Knock-down of DICAM was conducted with lentivirus expressing DICAM-specific shRNA in HK2 renal epithelial cells. RESULTS: The kidney tissue of cisplatin-induced ATN model revealed that the expression of DICAM was increased at ATN day 3. DICAM KO mice showed more severe semi-quantitative ATN histologic score as well as a significantly higher expression of LCN2 than WT. While apoptotic cells assessed by TUNEL assay were similar in DICAM KO and WT mice, the tissue protein level of cleaved caspase-3 was increased in DICAM KO mice. In addition, the necrotic cells with HMGB1 immunostaining were more prominent in DICAM KO and serum creatinine, the later marker for ATN was significantly higher on day 3 in DICAM KO. In molecular level, DICAM KO mice had a significantly lower expression level of ZO-1 and Claudin-1 in ATN tissue than WT.
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DICAM was co-localized with ZO-1 and Claudine-1 in HK2 cells in vitro. The knockdown of DICAM attenuated junction formation of HK2 cells as well as the expression of ZO-1 and Claudine-1. CONCLUSIONS: Loss-of-function of DICAM revealed more severe tubular damage in cisplatin-induced ATN, which was accompanied by decrease of junctional molecules such as Zo-1 and Claudin-1. DICAM as an adhesion molecule of JAM family can be involved in the maintenance of epithelial junctional stability during ATN. Tatsuya Pathophysiology, Meiji Pharmaceutical University, Tokyo, Japan INTRODUCTION AND AIMS: Aquaporin-11 (AQP11) is expressed at intracellular organelles such as the endoplasmic reticulum (ER). When we produced AQP11-null mice, we have found a striking phenotype of multiple large intracellular vacuole-like structures in all proximal tubular cells and limited hepatocytes in periportal area. They are derived from the ER. Since AQP11 functions as a water and glycerol channel, this vacuole formation was unexpected. To obtain insights into the mechanism for the vacuole formation, we employed a proteomic approach to identify key molecules for the hepatic vacuole formation. METHODS: Mouse livers from three week old AQP11-null mice with vacuolated hepatocytes and from their wild-type littermates were compared through their proteomes. Tissue samples were sonicated and digested in sodium deoxycholate buffer to increase the solubility of hydrophobic proteins and trypsin action. After labeling with tandem mass tagging (TMT) 6-plex, mixed samples were fractionated by C18-strong cation exchange stop-and-go extraction tips and separated by nano-flow HPLC (Easy-nLC) followed by mass spectrometer, Q-Exactive (Thermo Scientific).
FP020 PROTEOMIC ANALYSIS OF THE LIVER FROM AQP11 NULL MICE: HEPATOCYTES WITH INTRACELLULAR LARGE VACUOLES

RESULTS:
The analysis of six livers (three wild-types and three AQP11-null mice) each in two separate littermate sets identified 1113 overlapping proteins. KEGG pathway analysis revealed the decreased proteins related to biosynthesis of antibiotics and nitrogen/lipid metabolism in AQP11-null liver. The individual protein analysis revealed that 13 proteins were enhanced in AQP11-null liver more than 1.5 folds including cell matrix proteins (fibrinogen, keratin, EMILIN-1), cytochrome P450 4A (20-HETE synthase and fatty acid x-hydroxylase activities), RNA-binding protein 3 (protein synthesis enhancement), bile acid sulfotransferase-1 (elimination of bile acids) and thymidine phosphorylase (angiogenic factor). On the other hand, 21 proteins were depressed in AQP11-null livers less than 0.65 folds including 7-dehydrocholesterol reductase (DCHR7), carboxylesterase 3A (Ces3a)(detoxification), carbonic anhydrase 3(CAIII) (anti-oxidant) and mitochondrial ATP-synthase-coupling factor 6 (cell energy production). Of note, DCHR7 was decreased to one third of the wild-type, which is the final enzyme in the sterol synthetic pathway being present at the ER membrane. Interestingly, the genetic absence of DCHR7 causes Smith-Lemli-Opitz syndrome characterized by prenatal and postnatal growth retardation and microcephaly while AQP11-null mice also suffer from small head and body sizes and AQP11 is localized at the ER. However, the blood total cholesterol levels of AQP11-null mice were normal with possible compensation by the residual normal hepatocytes. CONCLUSIONS: Our proteomic study on AQP11-null liver revealed the decrease of hepatic cholesterol synthesis, which may increase the fluidity of the membrane surface to be made more permeable to small water-soluble molecules accumulating into intracellular vacuoles. Moreover, the decreased molecules for anti-oxidant and detoxification may delay their degradation.
FP021 RENAL KNOCKOUT OF THE NEONATAL FC RECEPTOR (FCRN) IS NOT ASSOCIATED WITH CHANGES IN ALBUMIN METABOLISM
Esben Axelgaard
INTRODUCTION AND AIMS:
The neonatal Fc receptor (FcRn) is a membrane receptor involved in transport of IgG in the gut and the placenta. FcRn has been shown also to bind albumin, and in the kidney FcRn has been implicated in the transtubular transport of albumin. It has been hypothesized that FcRn is essential for the recovery of large amount of filtered, intact albumin and thus for maintaining normal albumin metabolism and plasma albumin levels. While the proximal tubule receptors cubilin and megalin are regarded the major receptors for uptake of albumin, it was proposed that FcRn binds and mediates transcytosis of albumin following dissociation from cubilin/megalin in the endosomal compartment. METHODS: Utilizing the Cre/lox conditional knockout system we specifically targeted FcRn expression in the mouse kidney. We used anti-prominin-1 antibody coated magnetic beads to purify proximal tubule cells from mouse kidney homogenates. FcRn, megalin and cubilin gene expression was analysed by quantitative real-time PCR, while plasma and urine protein levels were measured by ELISA. 
